Kevin Whelan

1.2k total citations
16 papers, 685 citations indexed

About

Kevin Whelan is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, Kevin Whelan has authored 16 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 9 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in Kevin Whelan's work include Neurotransmitter Receptor Influence on Behavior (9 papers), Nicotinic Acetylcholine Receptors Study (6 papers) and Receptor Mechanisms and Signaling (5 papers). Kevin Whelan is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (9 papers), Nicotinic Acetylcholine Receptors Study (6 papers) and Receptor Mechanisms and Signaling (5 papers). Kevin Whelan collaborates with scholars based in United States, China and Japan. Kevin Whelan's co-authors include G. Kenneth Lloyd, Frédérique Menzaghi, Victoria B. Risbrough, Andrew J. Grottick, Dominic P. Behan, Hussien Al‐Shamma, William Thomsen, Brian M. Smith, Michael Morgan and Weichao Chen and has published in prestigious journals such as Brain Research, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Kevin Whelan

16 papers receiving 661 citations

Peers

Countries citing papers authored by Kevin Whelan

Since Specialization

Citations

This map shows the geographic impact of Kevin Whelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Whelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Whelan more than expected).

Fields of papers citing papers by Kevin Whelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Whelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Whelan. The network helps show where Kevin Whelan may publish in the future.

Co-authorship network of co-authors of Kevin Whelan

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Whelan. A scholar is included among the top collaborators of Kevin Whelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Whelan. Kevin Whelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Diazepine Agonists of the 5-HT_2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352) 2025 ·Journal of Medicinal Chemistry ·Albert Ren, Xiuwen Zhu, Juerg Lehmann, (unknown), Thomas O. Schrader, (unknown), (unknown), John Frazer, David J. Unett, Andrew J. Grottick, Kevin Whelan, Michael Morgan, Carleton R. Sage, Nuggehally R. Srinivas, Dewey McLin, Graeme Semple	2
2	Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays 2019 ·Bioorganic & Medicinal Chemistry Letters ·Albert Ren, Xiuwen Zhu, Konrad Feichtinger, (unknown), (unknown), Thomas O. Schrader, (unknown), (unknown), (unknown), John Frazer, David J. Unett, Andrew J. Grottick, Kevin Whelan, Michael Morgan, Carleton R. Sage, Graeme Semple	3
3	Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor 2016 ·Bioorganic & Medicinal Chemistry Letters ·Thomas O. Schrader, (unknown), Albert Ren, Konrad Feichtinger, (unknown), (unknown), Chunrui Wu, (unknown), (unknown), Joel Gatlin, (unknown), (unknown), Kevin Whelan, Carleton R. Sage, Andrew J. Grottick, Graeme Semple	6
4	Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat 2014 ·Psychopharmacology ·Andrew J. Grottick, Kevin Whelan, (unknown), Dominic P. Behan, Michael Morgan, Carleton R. Sage	10
5	Identification of fused bicyclic heterocycles as potent and selective 5-HT2A receptor antagonists for the treatment of insomnia 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Brett R. Ullman, (unknown), (unknown), (unknown), (unknown), Konrad Feichtinger, John Frazer, (unknown), Kevin Whelan, (unknown), Andrew J. Grottick, Hussien Al‐Shamma, Graeme Semple	9
6	Diet‐Induced Models of Obesity (DIO) in Rodents 2012 ·Current Protocols in Neuroscience ·Didier Bagnol, Hussien Al‐Shamma, Dominic P. Behan, Kevin Whelan, Andrew J. Grottick	20
7	Synthesis and in Vivo Evaluation of Phenethylpiperazine Amides: Selective 5-Hydroxytryptamine_2AReceptor Antagonists for the Treatment of Insomnia 2010 ·Journal of Medicinal Chemistry ·Yifeng Xiong, Brett R. Ullman, (unknown), (unknown), (unknown), (unknown), Peter I. Dosa, Konrad Feichtinger, Bradley R. Teegarden, John Frazer, (unknown), Yun Shan, Kevin Whelan, (unknown), Andrew J. Grottick, Graeme Semple, Hussien Al‐Shamma	6
8	Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: In vitro profiling and in vivo evaluation 2009 ·Bioorganic & Medicinal Chemistry Letters ·Graeme Semple, Thuy-Anh Tran, (unknown), (unknown), Sangdon Han, (unknown), (unknown), Martin D. Casper, Ning Zou, (unknown), William Thomsen, Kevin Whelan, Dipanjan Sengupta, Michael Morgan, Yoshinori Sekiguchi, (unknown), Shigeyuki Chaki, Andrew J. Grottick	3
9	Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization 2008 ·Journal of Pharmacology and Experimental Therapeutics ·William Thomsen, Andrew J. Grottick, (unknown), (unknown), Stephen Espitia, (unknown), Kevin Whelan, Michael Wade Martin, Michael Morgan, Weichao Chen, Hussien Al‐Shamma, Brian M. Smith, Derek Chalmers, Dominic P. Behan	320
10	Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity 2005 ·Bioorganic & Medicinal Chemistry Letters ·Brian M. Smith, Jeffrey M. Smith, James H. Tsai, Jeffrey A. Schultz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Dipanjan Sengupta, William Thomsen, (unknown), Kevin Whelan, (unknown), Robert R. Webb, Nigel R. A. Beeley	70
11	Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine 2004 ·Brain Research ·Tadimeti S. Rao, Aida Sacaan, Frédérique Menzaghi, Richard T. Reid, (unknown), Lucia Correa, Kevin Whelan, Jean‐Michel Vernier	7
12	Cognitive Enhancing Properties and Tolerability of Cholinergic Agents in Mice: A Comparative Study of Nicotine, Donepezil, and SIB-1553A, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors 2003 ·Neuropsychopharmacology ·Bruno Bontempi, Kevin Whelan, Victoria B. Risbrough, G. Kenneth Lloyd, Frédérique Menzaghi	63
13	SIB-1553A, (±)-4-{[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio}phenol Hydrochloride, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors with Putative Cognitive-Enhancing Properties: Effects on Working and Reference Memory Performances in Aged Rodents and Nonhuman Primates 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Bruno Bontempi, Kevin Whelan, Victoria B. Risbrough, Tadimeti S. Rao, Jerry J. Buccafusco, G. Kenneth Lloyd, Frédérique Menzaghi	49
14	Effects of a Novel Cholinergic Ion Channel Agonist SIB-1765F on Locomotor Activity in Rats 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Frédérique Menzaghi, Kevin Whelan, Victoria B. Risbrough, Tadimeti S. Rao, G. Kenneth Lloyd	40
15	Interactions between a Novel Cholinergic Ion Channel Agonist, SIB-1765F and L-DOPA in the Reserpine Model of Parkinson’s Disease in Rats 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Frédérique Menzaghi, Kevin Whelan, Victoria B. Risbrough, Tadimeti S. Rao, G. Kenneth Lloyd	34
16	Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Aida Sacaan, Frédérique Menzaghi, Julia Dunlop, Lucia Correa, Kevin Whelan, G. Kenneth Lloyd	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact